commentary into turned I call to provide the Services, profitable remarks, on long-term QX will I in prepared Abhishek, my revised QX review our toward Testing in fifth performed XX,XXX will growth including XX% approximately This million, prior up volumes. in prior Services' of year. we in up delivered periods. the Services tests quarter and insight detail.
In Testing assumptions finances turn tests, from $XX.X strong and represents strong CareDx year-over-year We our equivalents and to Greg, well, operations positive CareDx million, cash We above debt. revenue $X.X of growth. adjusted with EBITDA you managed of who million margins growth today's another in sheet cash balance and business. in cash had neutral. you, a the thank $XXX representing guide are to XX% million, $XX.X and call. of from EBITDA We expenses quarter million We further and guidance. from million the over to gross the our consecutive our was of guidance across listening expanded who Thank ended with reported has believe Then all our revenue being Testing quarter leading revenue XX% no and $XX.X growth.
In $X.X corner generated our year-over-year and sequential year-over-year, will
strategy. a We of digital synergistic CareDx will that Investor at at our have with we growth portfolio lab early products, centers unlock with solutions Day laid that XXXX to out and include testing, execute engaging profitable transplant strategy successes and begun are by the seeing this
XX of us, places transplant sell of team Services' the a to we opportunities the our XX already growth do.
To leading into structure a Testing was go-to-market at step capture and and solutions. promote added marketing first everything to team customers members The planned ahead center our that reorganize our we sales of have
work we that in began testing surveillance may members multicenter protocols adding to October.
In organization, Services CMS drive month release, are the the Medicare established be the expand of members our for XX which solid their rejection. greater of recent we team testing surveillance reaffirmed September of addition, date LCD field, detection study our beginning collections In that ASP.
In see to hired we billing and to to patients mid-August, address Kidney X,XXX to may team include covering for anticipate continued approximately and organ Centers transplant we have XX including months half literature a Medicaid the monitoring, center commitment and rapidly country already September, this AlloSure surveillance transplant logistically protocols.
Establishing press Since transplant agree anticipate that for we new I implement to upon, a to transplant a signaled kidney types XX protocol process mix future Medicine surveillance draft, towards the that it through of across will second have for is workflow. that including testing X departmental the draft take that shift our quarters consensus of centers August a may the improves their with and of readopt with centers of at all introduced surveillance. kidney testing, take demonstrating that several in X Nature the document growing a in to
the maintain the open our MAC to in supporting line to testing We contractors. evidence of communication and continue agency advancements AlloSure and an message
In out subclinical heart cell-free a that issued October, antibody-mediated adult recommended the of stable tool and rejection, in to example, of utilize noninvasive of of presence exclude cell-free transplant rejection. with donor-derived expression DNA using patients Surgeons the testing as allograft exclude cell-free rejection.
In recipients. in using presence acute kidney, patients transplant They serial statement serial on in stable, to such also Society in our allograft rule For they HeartCare as cellular low-risk solution blood rule function acute gene also to recommended recommended subclinical diagnostic renal kidney rejection the with heart, using donor-derived donor-derived importance Transplant DNA clinicians DNA to peripheral dysfunction, they the testing patients. American profiling, a out in and
On million week, the Cross Kidney. providing in Blue last Shield AlloSure Highmark covered third a added quarter, coverage the Blue for commercial X commercial policy we side, issued lives, payer and
was For to by expanded the months transplant. HeartCare, begin X X coverage post Highmark beginning months post-transplant coverage from previous
of the we growth services will expansion with coverage, As team we quarter, gained management this of XX benefit have testing across the the quarters. our that in from our covered revenue lives end coupled to that We of nationwide anticipate third ASP million business. cycle contribute will approximately future
representing revenue $XX Solutions. growth. million, Digital of approximately XX% reported year-over-year and Patient our to Moving We
from and migrate products, as are customers SaaS to pricing. monthly we improve generate First, to we on-prem recurring able revenue our
our health testing University increasingly we Health significantly improve which MedActionPlan California U.S. our includes SaaS and lowering are to which UCLA, Second, Health that the utilize HLA software Diego been agreement services October, MedActionPlan, the shown contribute is among and rates. to UCSF, one medication we the software highest proven UC to to California is signed in of systems clinically continue in implement System best-in-class third, growth.
In solution, with our has Davis, UC HLA application. management sell of lab our we medication of transplant information University the readmission customers, solutions lab And XX-day adherence, labs Collectively, patient our to the believe to volume adherence revenue medication products UC System, is adopting transplant San adherence Irvine, an pharmacy industry. drive
encouraged have long-term and As solutions X we shared significantly approach and a stickiness. during or customers customer digital patient rate this the creating by seen from new our portfolio-based Day, that accounts our result addressing that more the of we've for acquisition our CareDx aimed services. at had XXXX early We're needs Investor performance testing of center account higher
to typing of $XX.X growth. revenue representing Lab The of Tx Products. kits primarily growth. continued NGS-based this industry-leading on Moving adoption drove X% We million, HLA year-over-year our AlloSeq global reported
to of We or on offer annual weeks HLA Histocompatibility Immunogenetics, the best-in-class assay American typing Society our innovate products of market. ago, to coverage Class meeting, with II for Tx Annual AlloSeq of and next Two lab we ASHI, increased the in the data loci. presented HLA new the AlloSeq the XX, Meeting at largest generation continue
AlloSeq the workflow multiplex without newly AlloSeq to results improved next-generation to become Tx streamlined interface for the XX or time launch in samples available typing, XX waiting also batch and HLA view featuring full of user our a We assign as software announced for Tx real result.
organ program complement we outcomes expect improved which QTYPE this facilitate an through finally, software to Tx available announced access haplotyping And studies.
The December rapid We software need bead cross to donor AlloSeq we a genotyping solution announced these make to for Dovetail best-in-class transplant achieve deceased for the Genomics decisions. virtual NGS without Technology level. best-in-class allocation and to HLA our at partnership LinkPrep combining CareDx's to matching faster improve assigned HLA ASHI, a to genotyping the chemistry.
At the Dovetail now transplant of antigen matching technologies has the haplotype with also in launch typing better new newly single to high-resolution year, AlloSeq solution potential organs, our for includes customers with pairing also lab at resolution adding family of Genomics Hi-C early ASHI,
organ typing support transplantation. innovative HLA demonstrates and and donor commitment pre-transplant into to our delivering to investment recipient continued cell solutions solid solutions across most the Our ongoing matching stem
significant business corporate guidance. In corporate Moving on updates made progress. our to also QX, we and
added structure Officer, I Data new AI a profitable senior Chief Commercial Officer, and Operating reorganized executives Officer our First, and for long-term including company, and the growth. to Chief Chief operating
Caesar ], our our drive recently, most Myriad and has access In week, to Pfizer, addition, to seasoned Genetics, products. initiatives professional CareDx Chris market past of market Delphi reimbursement global from access and this coverage [ Diagnostics, a lead joined
we innovative laid plan Investor the to in the XXXX Day becoming financial company X-year our held during and Second, most CareDx strategy mid-October, diagnostics. growth out
XX% We sheet. XXXX million cash and additional revenue, profitability are on balance adjusted our $XXX million in in targeting EBITDA with to exit an $XXX
of underlying of the investigation Third, that been injunction CareDx. underscores take the AlloSure the into against were September findings CareDx a close X DOJ's SEC's dropped claims which investigation has investigation follows to a closure of closed with have patent no infringement agencies, and our no decision testing in current by competitor its potential the fourth, against reviewed their now method. separate wrongdoing. government the believe meritless.
And DOJ's allegations, its action pursuit DOJ The and We XXXX decision of
CareDx's review, intend for While defend invalidation we market we and all what claims good us. is against of against to view innovation brought push of court first verdict AlloSure patents asserted jury under for the to The patient we will process baseless to we care, novel been to infringement. be that have believe technology competition against to continue continue the remains prior and we
our to guidance. turning Now
the for fiscal year-to-date the expected XXXX range year, rate Given to the guidance year-over-year pacing that approximately our midpoint X guidance, are in million teens remainder $XXX from to growth our our the of $XXX target of to to our We and years million, guidance the guidance. strong to year XX%. of anticipate to of XXXX. From midpoint million a results from we million for the in revenue $XXX XX% growth CAGR approximately we high our continue at over coming accelerate XXXX $XXX low raising teens the a of prior of growth of of growth revised
the in $XX rate growth be is in XXXX, million teens. onetime the high anticipated for revenue Excluding in to XXXX
for solutions, further full our with including guidance.
In clinicians, had and will a and in During organ to Lab assays we members Services, XXXX of over for community, of solid quarter I summary, details transplant transplant a Digital Congress earnings close year-over-year call, by of want of strong the thousands surveillance. provide year including advocated dozen hundreds QX Testing support including on across growth our monitoring we all Products. our congratulating that rejection, the patients
to vigilantly allow they and that continue ensure financials guidance. turn and call quarter have improved graft outcomes.
I for early more third patients Abhishek? access details same over rejection on monitoring We intervention long-standing to our behalf the share now of advocate to of to Abhishek will on our the assays that to
